Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Reviews
Nature Immunology
Nature Cell Biology
Nature Genetics
news@nature.com
Nature Conferences
Dissect Medicine
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Article
Nature Medicine  10, 1216 - 1221 (2004)
Published online: 24 October 2004; | doi:10.1038/nm1124

Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis

Hong Wang1, 5, Hong Liao1, 5, Mahendar Ochani2, Marilou Justiniani1, Xinchun Lin3, Lihong Yang2, Yousef Al-Abed1, Haichao Wang4, Christine Metz1, Edmund J Miller3, Kevin J Tracey2 & Luis Ulloa1

1  The Center for Immunology and Inflammation, North Shore-LIJ Research Institute, North Shore University Hospital, 350 Community Drive, Manhasset, New York 11030, USA.

2  Center for Patient-Oriented Research, North Shore University Hospital, 350 Community Drive, Manhasset, New York 11030, USA.

3  Department of Surgery, North Shore University Hospital, 350 Community Drive, Manhasset, New York 11030, USA.

4  Department of Emergency Medicine, North Shore University Hospital, 350 Community Drive, Manhasset, New York 11030, USA.

5  These authors have contributed equally to this work.

Correspondence should be addressed to Luis Ulloa lulloa@nshs.edu
Physiological anti-inflammatory mechanisms can potentially be exploited for the treatment of inflammatory disorders. Here we report that the neurotransmitter acetylcholine inhibits HMGB1 release from human macrophages by signaling through a nicotinic acetylcholine receptor. Nicotine, a selective cholinergic agonist, is more efficient than acetylcholine and inhibits HMGB1 release induced by either endotoxin or tumor necrosis factor-alpha (TNF-alpha). Nicotinic stimulation prevents activation of the NF-kappaB pathway and inhibits HMGB1 secretion through a specific 'nicotinic anti-inflammatory pathway' that requires the alpha7 nicotinic acetylcholine receptor (alpha7nAChR). In vivo, treatment with nicotine attenuates serum HMGB1 levels and improves survival in experimental models of sepsis, even when treatment is started after the onset of the disease. These results reveal acetylcholine as the first known physiological inhibitor of HMGB1 release from human macrophages and suggest that selective nicotinic agonists for the alpha7nAChR might have therapeutic potential for the treatment of sepsis.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Can nicotine treat sepsis?

Nature Medicine News and Views (01 Nov 2004)

It takes nerve to dampen inflammation

Nature Immunology News and Views (01 Aug 2005)

See all 4 matches for News And Views
 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

naturejobs

Competing financial interests
Figures & Tables
Supplementary info
See also: News and Views by Matthay & Ware
Export citation
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Medicine
ISSN: 1078-8956
EISSN: 1546-170X
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2004 Nature Publishing Group | Privacy policy